| Literature DB >> 233160 |
J M Kane, A Rifkin, F Quitkin, D Nayak, K Saraf, J R Ramos-Lorenzi, D F Klein, E J Sachar.
Abstract
To test the clinical efficacy of low dose fluphenazine decanoate (1.25 mg to 5.0 mg biweekly), we carried out two separate experiments: (1) an open trial in 57 schizophrenic outpatients, lasting 6 months; (2) a double-blind, placebo-controlled discontinuation study in a subgroup of patients who maintained good remission throughout the entire 6-month open trial. The results suggest that lower doses of fluphenazine decanoate than those usually used may be effective in preventing psychotic relapse while keeping total cumulative dosage to a minimum.Entities:
Mesh：
Substances：
Year: 1979 PMID： 233160 DOI： 10.1016/0165-1781(79)90016-7
Source DB: PubMed Journal: Psychiatry Res ISSN： 0165-1781 Impact factor: 3.222